ELI LILLY & Co (LLY) Factsheet
Earnings-call transcript: none · IR deck: cataloged — watch a real agent read these end-to-end →
ELI LILLY & Co (LLY) Stock Analysis
Analysis from 10-Q filed 2026-10-29. Data as of Q3 2026.
Overall Grade: F (Concerning)
Grade F (Concerning). ROIC 45.3%. FCF margin 22.7%. D/E 1.2x. Source: 10-Q filed 2026-10-29.
| Metric | Value | Context |
|---|---|---|
| ROIC | 45.3% | Above industry average |
| FCF Margin | 22.7% | Strong cash generation |
| Debt/Equity | 1.2x | Moderate leverage |
ROIC 45.3% — Top 5% of sector peers. FCF margin 22.7% — Top 25%.
Explore ELI LILLY & Co: Earnings History | Overview
Programmatic access: Available via MCP at mcp.metricduck.com. Tools for LLY: get_company_overview, get_filing_index (lens: debt_stress, management_outlook, risk_trajectory), get_filing_section, get_metric_history, compare_companies, screen_filing_signals.
Profitability: ELI LILLY & Co earns 45.3% ROIC, Top 5% in Healthcare
ROIC TTM 45.3%, sector median -7.7%, Top 5%. DuPont: NOPAT margin 40.7% × asset turnover 0.7x. Gross margin 83.6%. Operating margin 51.3%. Source: 10-Q filed 2026-10-29.
| Metric | LLY | Rating | Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 45.3% | Excellent | Above sector median of -7.7% |
| Return on Equity (ROE) | 89.2% | Excellent | Efficient use of shareholder equity |
| Gross Margin | 83.6% | Excellent | Strong pricing power |
| Operating Margin | 51.3% | Excellent | Efficient operations |
Cash Flow: ELI LILLY & Co generates $19.7B FCF at 22.7% margin, positive NaN/8 quarters
FCF TTM $19.7B. FCF margin 22.7%, Top 25%. OCF/Net income 1.1x. Positive FCF in NaN/8 trailing quarters. Source: 10-Q filed 2026-10-29.
| Metric | LLY | Rating | Context |
|---|---|---|---|
| Free Cash Flow Margin | 22.7% | Excellent | Excellent cash conversion |
| Free Cash Flow (TTM) | $19.7B | Good | Positive cash generation |
| OCF/Net Income | 1.1x | Excellent | High earnings quality |
| FCF Consistency (8Q) | N/A | Warning | Variable cash flow |
Balance Sheet: ELI LILLY & Co at 1.2x leverage, 34.7x interest coverage
Debt/Equity 1.2x. Total debt $49.5B, cash & investments $5.0B. Interest coverage 34.7x. Source: 10-Q filed 2026-10-29.
| Metric | LLY | Rating | Context |
|---|---|---|---|
| Debt to Equity | 1.2x | Adequate | Moderate leverage |
| Net Cash Position | $-44.5B | Warning | Net debt position |
| Interest Coverage | 34.7x | Excellent | Comfortable debt service |
Valuation: ELI LILLY & Co trades at 48.8x earnings
P/E 48.8x. EV/Sales 16.1x. FCF yield 1.5%. Dividend yield 0.5%. Source: 10-Q filed 2026-10-29.
| Metric | LLY | Rating | Context |
|---|---|---|---|
| P/E Ratio | 48.8x | Adequate | Premium valuation |
| EV/Sales | 16.1x | Warning | Growth premium priced in |
| FCF Yield | 1.5% | Warning | Lower cash yield |
| Dividend Yield | 0.5% | Adequate | Growth focus over income |
Capital Allocation: ELI LILLY & Co returns 0.9% shareholder yield, reducing shares 0.5% YoY
Total shareholder yield 0.9% (div 0.5% + buyback 0.4%). Share count -0.5% YoY. Capital returned $11.8B TTM. Source: 10-Q filed 2026-10-29.
| Metric | LLY | Rating | Context |
|---|---|---|---|
| Total Shareholder Yield | 0.9% | Adequate | Dividend + buyback yield combined |
| Buyback Yield | 0.4% | Adequate | Minimal buyback activity |
| Share Count Change (YoY) | -0.5% | Adequate | Net share reduction (accretive) |
| Total Capital Returned (TTM) | $11.8B | Good | Dividends + buybacks returned to shareholders |
Sector Rankings
| Metric | Value | Percentile | vs Median |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 45.3% | Top 5% | - |
| Free Cash Flow Margin | 22.7% | Top 25% | 7.5x above |
| Gross Margin | 83.6% | Top 25% | 1.3x above |
| Operating Margin | 51.3% | Top 5% | - |
| Return on Equity (ROE) | 89.2% | Top 5% | - |
| P/E Ratio | 48.8x | N/A | - |
Financial Scorecard
| Metric | LLY | Rating | Sector Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 45.3% | Excellent | Top 5% of sector (median: -7.7%) |
| Free Cash Flow Margin | 22.7% | Excellent | Top 25% of sector (median: 3.0%) |
| Gross Margin | 83.6% | Excellent | Top 25% of sector (median: 63.8%) |
| Debt to Equity Ratio | 122.9% | Adequate | Elevated but manageable |
| P/E Ratio (Price-to-Earnings) | 48.8x | Adequate | High expectations priced in |
| Free Cash Flow Yield | 1.5% | Warning | Growth-focused valuation |
Frequently Asked Questions
Q: What is ELI LILLY & Co's Return on Invested Capital (ROIC)?
ELI LILLY & Co (LLY) has a trailing twelve-month Return on Invested Capital (ROIC) of 45.3%. The 8-quarter median ROIC is 42.7% with a improving trend. Sector median -7.7%. Source: 10-Q filed 2026-10-29.
Q: What is ELI LILLY & Co's Free Cash Flow Margin?
ELI LILLY & Co (LLY) has a free cash flow margin of 22.7%, generating $19.7 billion in free cash flow over the trailing twelve months. Source: 10-Q filed 2026-10-29.
Q: What is ELI LILLY & Co's P/E ratio and how does it compare to peers?
ELI LILLY & Co (LLY) trades at a P/E ratio of 48.8x, which is above the sector median of N/A. EV/Sales 16.1x. FCF yield 1.5%. Source: 10-Q filed 2026-10-29.
Q: Does ELI LILLY & Co pay a dividend?
ELI LILLY & Co (LLY) currently pays a dividend yield of 0.5%. Total shareholder yield (dividend + buybacks) 0.9%. Source: 10-Q filed 2026-10-29.
Q: How much debt does ELI LILLY & Co have?
ELI LILLY & Co (LLY) has a debt-to-equity ratio of 1.2x with total debt of $49.5 billion. Interest coverage 34.7x. Net debt $44.5 billion. Source: 10-Q filed 2026-10-29.
Q: What is ELI LILLY & Co's revenue and earnings growth?
ELI LILLY & Co (LLY) grew revenue by 45.5% year-over-year. EPS +50.7% YoY. Source: 10-Q filed 2026-10-29.
Q: Is ELI LILLY & Co buying back stock?
ELI LILLY & Co (LLY) repurchased $5.8 billion of stock over the trailing twelve months. This represents a buyback yield of 0.4%. Share count -0.5% YoY. Source: 10-Q filed 2026-10-29.
Q: How does ELI LILLY & Co compare to competitors in Healthcare?
Compared to other companies in Healthcare, ELI LILLY & Co (LLY) shows: ROIC 45.3%, sector median -7.7% (Top 5%). FCF margin 22.7%, sector median 3.0% (Top 25%). Gross margin 83.6%, 19.8pp above sector median. These rankings are based on MetricDuck's analysis of all Healthcare companies with available SEC filings.
Q: What warning signs should I watch for with ELI LILLY & Co?
No quantitative warning flags fired for ELI LILLY & Co (LLY) on margin trend, FCF trend, ROIC trend, or leverage thresholds. Source: 10-Q filed 2026-10-29.
Data Source: Data sourced from 10-Q filed 2026-10-29. TTM metrics as of Q3 2026.
Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.
Scope: This analysis covers SEC filing fundamentals — profitability, cash flow, balance sheet, and valuation metrics. For analyst estimates and price targets, consult sell-side research.
This analysis is for informational purposes only and does not constitute investment advice.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms